iBio, Inc. (NASDAQ: IBIO)

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence and machine learning to develop precision antibody therapeutics for cardiometabolic and obesity indications. The company focuses on discovering and advancing biologics that address limitations of existing treatments, such as muscle loss and weight regain associated with GLP‑1 receptor agonists. Its core activities involve target identification, antibody design using its AI‑driven epitope‑steering platform, and preclinical validation of candidates. iBio conducts its research and development in a San Diego laboratory where computational scientists and biologists work side‑by‑side to accelerate the path from concept to lead selection.

iBio generates revenue primarily through collaboration and licensing agreements with partners. Upfront payments, milestone payments, and potential royalty streams arise from alliances such as the one with AstralBio, which include fees for target selection and options to license additional targets. The company may also earn revenue by out‑licensing its AI technology platform or specific antibody programs to third parties in therapeutic areas outside its core focus. As a preclinical stage entity, iBio does not currently sell commercial products.

Within the biotechnology industry, iBio occupies a niche as an AI‑enabled antibody developer targeting obesity and cardiometabolic diseases. It competes with large integrated pharmaceutical firms such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., and Merck & Co., which have approved GLP‑1 therapies and substantial commercial scale. iBio differentiates itself through its proprietary AI epitope‑steering engine, StableHu optimization tools, and modular technologies like EngageTx and ShieldTx, which aim to improve developability, reduce immunogenicity, and enable conditionally activated antibodies. The company also faces competition from other specialized biotech firms working on muscle‑preserving obesity therapies, including Scholar Rock, Viking Therapeutics, and Keros Therapeutics.

iBio’s customer base consists primarily of biotechnology and pharmaceutical partners with whom it engages in research collaborations, licensing, and co‑development arrangements. The company has disclosed a collaboration with AstralBio for multiple targets in the obesity and cardiometabolic space, and it references potential out‑licensing opportunities to larger drug developers. While specific names beyond AstralBio are not disclosed in the filing, the typical customers are entities seeking access to iBio’s antibody discovery platform or interested in acquiring rights to its preclinical candidates.